SVNT is scheduled to announce the pricing for Krystexxa on Tuesday, November 30th.
Estimates appear to range from as low as $20,000 for a year's treatment to $50,000 for a year's treatment.
With treatment bi-weekly, a year's treatment would include 26 intravenous administrations of Krystexxa.
I am tending to expect a "headline" price near or even above the high end of the analyst range for two main reasons: It will maximize the amount that is reimbursed by insurers and Medicare/Medicade/VA, and it will tend to maximize the bid level if they get a takeover offer.
Why sell yourself short?
SHIPMENT of Krystexxa will begin on November 30th, and the drug will be available for prescription on December 1.
Many Savienters have been waiting for this day for many years....
Good luck to SVNT employees and its shareholders
No comments:
Post a Comment